

In this Issue:

Quality Improvement Updates	2
Medicaid Program Updates	3
Medical Policy Updates	4
Pharmacy Updates	6

MVP Provider Directory

You can search the current MVP Provider Network for primary care physicians and specialists. Visit mvphealthcare.com and select **Find a Doctor**.

Un-Cashed Checks?

Visit longlostmoney.com to see if MVP has any un-cashed checks in your name or in the name of your business.

MVP Professional Relations

MVP Corporate	
Headquarters	1-888-363-9485
Southern Tier	1-800-688-0379
Central New York	1-800-888-9635
Midstate New York	1-800-568-3668
Mid-Hudson	1-800-666-1762
Buffalo/Rochester	1-800-684-9286

Denise V. Gonick

President & CEO
MVP Health Care, Inc.

We welcome your comments.

HEALTHY PRACTICES
MVP HEALTH CARE
PROFESSIONAL RELATIONS DEPT
PO BOX 2207
SCHENECTADY NY 12301



mvphealthcare.com

Professional Relations Updates

CMS Medicare Benefits and Beneficiary Protections for Plan-Directed Care

Per the Centers for Medicare & Medicaid Services (CMS) regulation, when an MVP Medicare Advantage plan member receives items and services from an MVP-contracted provider or is referred to a non-contracted provider by an MVP-contracted provider, he or she will generally be deemed to believe that those items or services are covered benefits under his or her Medicare Advantage policy. The member can only be held liable for the applicable in-plan cost share (co-pay, co-insurance, or deductible).

If you, as an MVP-contracted provider believe an item or service may not be covered or could be covered only under specific conditions, your office or the member must request a pre-service organization determination from MVP. The Medicare Advanced Beneficiary Notice or other forms of prior notice are not applicable to Medicare Advantage members.

CMS expects providers to coordinate with MVP before referring a patient to a non-contracted provider. This important step will ensure that our members are receiving medically-necessary services covered by their MVP Medicare Advantage plan.

Visit cms.gov and search for *Medicare Managed Care Manual, Chapter 4- Benefits and Beneficiary Protections, Section 160* for more information.

If you need to request a pre-service organization determination prior to providing a service or referring a member to a non-contracted provider, please call **1-800-684-9286**.

Provider Satisfaction Survey Mailing

MVP has mailed our annual General Satisfaction Survey to all of our providers. The survey was sent at the end of October. If you have not received it as of yet, please be look for it.

All respondents are entered into a drawing for a \$50 VISA gift card. MVP values your feedback, and we would appreciate it if you and your staff could take a few moments to complete the survey and return it to MVP.

Provider Demographic Changes

MVP makes every effort to ensure a provider's demographic information is accurate in our systems. If you or your practice have changes in demographic and/or participation status, it is important to promptly notify MVP.

Examples of status changes are:

- No longer accepting patients
- Changes of address, phone number, or tax ID number

To report demographic changes to MVP, please complete a *Provider Change of Information* form. To download the form, visit mvphealthcare.com and select *Providers*,

(Continued on page 2)

(*Provider Demographic Changes continued from page 1*)

then *Forms*, and then the appropriate form under *Provider Demographic Change Forms*. Please return the completed demographic change form to the appropriate email.

East New York and Massachusetts

eastpr@mvphealthcare.com

Central, Mid-State, or Southern Tier New York

centralprdept@mvphealthcare.com

Rochester

RocProviderChanges@mvphealthcare.com

Mid-Hudson New York

MidHudsonprdept@mvphealthcare.com

Vermont

vpr@mvphealthcare.com

For more information, see Section 4 of the *MVP Provider Resource Manual*.

Quality Improvement Updates

Monitoring Kidney Disease in Patients with Diabetes

The Centers for Medicare and Medicare Services monitor the quality of care that Medicare members in Medicare Advantage Plans receive from their contracted physicians. These results are compared across Medicare Advantage plans across the country through the Medicare Star Ratings. One measure that is included in the Star Rating is Kidney Disease Monitoring in patients with Diabetes.

We want to thank you for the excellent care our physicians and ancillary providers continue to give all MVP members, your patients. This is a measure that we did not perform as well in this year. We do want to remind everyone about documentation and coding that is necessary to show that services are given.

A *Fast Fax* was sent earlier this year notifying physicians that MVP has created reference guidelines that will provide you and your staff with helpful tools that explain HEDIS measures as well as providing the CPT, HCPCS, and ICD-10 codes that count toward the completion of these measures.

To find this coding reference guide, visit **mvphealthcare.com** and select *Providers*, then *Quality Programs*, then *HEDIS 2017 Coding Reference Guide for Primary Care*. Information about Kidney Disease (Nephropathy) Monitoring in patients with Diabetes can be found on pages 16–17.

HEDIS/QARR Measure Spotlight

Healthcare Effectiveness Data & Information Set (HEDIS) is a nationally recognized set of health care quality measures that contribute significantly to MVP's NCQA (National Committee for Quality Assurance) accreditation score. MVP collects HEDIS data from claims information and by chart review in many offices across our service area. MVP monitors its performance in these measures on an ongoing basis and submits results to NCQA annually. The state and federal governments also monitor the HEDIS measure results to assess the quality of care that the members of health plans receive from their contracted physicians. The CMS Star Rating Program and New York State Quality Assurance Reporting Requirements (QARR) programs are two examples.

Results are also produced at the practice level for use in clinical reporting, allowing providers to see how they compare in relation to the health plan averages. Below is information on select HEDIS measures that relate to Behavioral Health.

If you have questions on compliance with any HEDIS measure, please contact Michael Farina at **518-388-2463** or **mfarina@mvphealthcare.com**.

AMM—Antidepressant Medication Management

This measure focuses on members with a diagnosis of Major Depression who were treated with an antidepressant medication (ages 18 and over). Two medication adherence rates are reported:

- 1. Effective Acute Phase Treatment**—members must remain on an antidepressant medication for at least 84 days (12 weeks).
- 2. Effective Continuation Phase Treatment**—members must remain on an antidepressant medication for at least 180 days (six months).

ADHD—Follow-Up Care for Children Prescribed ADHD Medication

This measure focuses on children ages 6–12 who were newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication. Two rates for follow-up visits are reported:

- 1. Initiation Phase**—children must have one follow-up visit with practitioner with prescribing authority within 30-days from when the medication was dispensed.
- 2. Continuation and Maintenance Phase**—in addition to the initial visit within 30 days, children must have two

additional visits within nine months after the Initiation Phase has ended.

We understand the challenges providers face to help educate patients and influence behavior change; especially when dealing with mental illness/substance abuse. We have various resources available to support your work—some of these are described below.

Primary Care Quality Reports

MVP produces several reports for physicians:

- **The Accountable Care Metrics (ACM)** report currently includes the AMM and ADHD measures. This report depicts the practices rate for each measure, compared to the health plan mean and goal.
- **The Gaps in Care** reports help providers identify members in need of certain visits/screenings. These reports are provided in Microsoft Excel and PDF format so that the practice can manipulate the patient lists to best suit their needs. They are delivered monthly via secure e-mail.

Throughout the year Clinical Reporting Coordinators visit practices to review their results and provide them with suggestions and tools to help improve their performance. For any questions on these reports or to schedule a visit, please contact Mike Farina at **518-388-2463** or **mfarina@mvphealthcare.com**.

Toll-Free Provider Consult Line

For our New York practitioners, Beacon Health Options offers a toll-free Provider Consult Line staffed by Board Certified Psychiatrists. These psychiatrists are available for telephonic consultation regarding all aspects of mental health and substance abuse treatment for children and adults, including appropriate use of psychotropic medications. PCPs as well as Specialists may call the Beacon Provider Consult Line for consultation at **1-877-241-5575**, Monday–Friday, 9 am–6 pm Eastern Time.

Clinical Guidelines and Tools

MVP has adopted clinical practice guidelines that address the behavioral health HEDIS measures. To access these guidelines, visit **mvphealthcare.com** and select *Providers*, then *Quality Programs*, then *Provider Quality Improvement Manual*, then *Behavioral Health*. Also located here are several tools providers can use for screening and treatment of these conditions.

Coordination of Care with Behavioral Health Providers

Individuals who are depressed or have other mental health/substance abuse issues often have trouble following through with recommendations. If you have referred a patient to a behavioral health provider, it is important that you follow-up with the patient to ensure the appointment was made in a timely manner and the individual attended it.

MVP strongly encourages Behavioral Health specialists to communicate with the members PCP. This allows both health care providers to have a complete overview of the member's health issues and concerns, in addition to coordinating any medications the member may receive. Communication and coordination among providers is essential to help reduce medical errors and improve quality, safety, and continuity of care.

Medicaid Program Updates

Improving Perinatal Care for Medicaid Members

As part of the MVP Health Care 2017-2018 Performance Improvement Project (PIP) for the New York State Department of Health, MVP will be working with OB/GYN providers to improve perinatal care for its Medicaid members. One of the goals is to improve utilization of Long-Acting Reversible Contraception (LARC) to support birth spacing that is optimal for maternal-fetal outcomes and patient choice.

Rapid repeat pregnancy (within 12–18 months following delivery) is possible if women unsuccessfully initiate or inconsistently use short-acting contraceptive methods after delivery. Brief inter-pregnancy intervals have been associated with an increased risk for several poor maternal and infant health outcomes, including preterm birth, low birth weight, and perinatal death. In addition, births that are unintended are not only at increased risk for adverse maternal and infant health outcomes, but are associated with other risks such as smoking and delayed prenatal care.

Long-Acting Reversible Contraception (LARC) has been shown to be an effective method of birth control with little effort required on the part of the individual after insertion. Several professional organizations publish recommendations on the use of LARC, including the American Congress of Obstetrics and Gynecology, the

American Academy of Pediatrics, and the Centers for Disease Control and Prevention. Recommendations generally include:

- Providing counseling on all contraceptive options for all women at risk of unintended pregnancy.
- Encouraging use of LARC for all appropriate candidates, including nulliparous women and teens.
- Adopting best practices for LARC insertion, including provision on the same day as requested, and at the time of delivery, miscarriage, or abortion.

Preliminary results from one of four cohorts reported in the New York State Department of Health's Medicaid Prenatal Care Quality Improvement Project tool indicated that only 11.4% of women received contraception immediately post-delivery. MVP will endeavor to increase the percentage of women ages 15–44 who are provided with LARC within three to 60 days post-delivery.

MVP has several tools available to support providers in achieving this goal. For more information visit mvphealthcare.com and select *Providers*, then *Quality Programs*, then *Provider Quality Improvement Manual* and view the *Women's Health* section.

Action required by December 1, 2017: Enroll with New York State Medicaid Programs

Effective January 1, 2018, Federal law requires that all Medicaid Managed Care and Children's Health Insurance Program (Child Health Plus) network providers be enrolled with New York State Medicaid programs. We are communicating how this requirement impacts providers and what steps need to be taken due to this regulatory change. The Medicaid provider enrollment process is to ensure appropriate and consistent screening of providers and to improve program integrity.

It's important for all providers to understand that applications must be received by CSRA, the Medicaid fiscal agent, by December 1, 2017.

New York State now requires that providers enroll as a Medicaid provider or you may be removed from the MVP Health Plan Medicaid Managed Care provider network. This new requirement to enroll as a Medicaid provider does not require providers to accept Medicaid fee-for-service patients.

Options for Enrollment

- If at one time you were a Medicaid provider, and your enrollment has lapsed (no longer actively enrolled), you

may be able to keep your original Provider Identification Number (PID), also known as MMIS ID, by indicating Reinstatement on the application.

- Practitioners may either enroll as a non-billing, Ordering/Prescribing/Referring/Attending (OPRA) provider, or as a Medicaid billing provider.
- Business, Group Practice, and Institutional provider types will be offered the option to enroll in Medicaid as a billing or non-billing (Managed Care Only) provider.

To enroll, providers will need to complete paperwork and submit it to New York State Medicaid. Please visit emedny.org and select *Provider Enrollment*, then navigate to your provider type to print and review the Instructions and the Enrollment form. At this website, you will also find a *Provider Enrollment Guide*, a *How Do I Do It? Resource Guide*, *FAQs*, and all the necessary forms related to enrollment in New York State Medicaid.

If you have questions during the New York State Medicaid Enrollment process, please contact the eMedNY Call Center at **1-800-343-9000**.

If you have any additional questions, please contact your MVP Professional Relations Representative or the MVP Provider Call Center at **1-800-684-9286**.

Medical Policy Updates

The MVP Quality Improvement Committee (QIC) approved the policies summarized below during the September meeting. Some of the medical policies may reflect new technology while others clarify existing benefits. *Healthy Practices* and/or *FastFax* will continue to inform your office about new and updated medical policies. MVP encourages your office to look at all of the revisions and updates on a regular basis in the *Benefits Interpretation Manual (BIM)*. To access the *Benefits Interpretation Manual*, visit mvphealthcare.com and *Sign In/Register*, then select *Resources*. The *Current Updates* page of the BIM lists all medical policy updates. If you have questions regarding the medical policies or wish to obtain a paper copy of a policy, contact your MVP Professional Relations Representative.

Medical Policy Updates Effective December 1, 2017

Acute Inpatient Rehabilitation: There are no changes to the medical policy criteria.

Alopecia Treatment *NEW Policy*: Alopecia Treatment is a new policy effective December 1, 2017. This policy addresses medical treatment for alopecia. Previously this policy was titled Alopecia, Wigs, and Scalp Prosthesis.

Alopecia, Wigs, and Scalp Prosthesis *ARCHIVED*: This policy is archived effective December 1, 2017. Please refer to Alopecia Treatment medical policy effective December 1, 2017.

Autism Spectrum Disorders New York State: This medical policy applies only to MVP plans that are required to follow the New York State Health Insurance Law for applied behavior analysis for autism spectrum disorder treatment. Refer to the member's individual plan certificate for benefit coverage for applied behavioral analysis.

Applied behavior analysis is not covered for MVP Managed Care Medicaid Products.

Automatic External Defibrillators *NEW Policy*: Automatic External Defibrillators is a new policy effective December 1, 2017. The policy addresses both wearable automatic defibrillators and non-wearable automatic defibrillators. There is both a Medicaid variation and a Medicare variation. Links to both the Medicaid and Medicare coverage criteria are listed in the policy.

Blepharoplasty, Brow Lift, and Ptosis Repair: There are no changes to the medical policy criteria.

Botulinum Toxin Treatment: There are no changes to the medical policy. Prior authorization is no longer required for CPT code 52287 effective January 1, 2017.

Breast Implantation: There are no changes to the medical policy criteria.

Breast Reconstruction Surgery: There are no changes to the medical policy criteria.

Clinical Guidelines Development, Implementation, and Review Process: There are no changes to the clinical guideline development, implementation, and review process.

Compression Stockings: There are no changes to the medical policy criteria. Compression stockings for Commercial products no longer require a disposable rider (effective immediately). For Medicaid products, gradient compression stockings are limited to two pairs twice per year for a total of four pairs per year.

Cranial Orthotics *NEW Policy*: Cranial Orthotics (e.g., helmet or cranial remodeling band) is a new policy effective December 1, 2017.

Erectile Dysfunction: There are no changes to the medical policy criteria.

Extracorporeal Shock Wave Therapy for Musculoskeletal Indications: There are no changes to the medical policy criteria. Extracorporeal Shock Wave Therapy has not been established in peer review literature to improve health outcomes in persons with musculoskeletal conditions. It is, therefore, considered not medically necessary.

Hearing Aid Services: There are no changes to the medical policy criteria. There is a Medicaid Managed Care variation with criteria for both monaural and binaural hearing aids.

Interspinous Process Decompression Systems (IPD): Interspinous Process Decompression Systems (IPD) are considered experimental and investigational and therefore are not covered. There is a Medicare variation that lists coverage criteria for the Interspinous Process Decompression System (X STOP®) for Medicare members when criteria are met. There is a Medicaid variation which states the Interspinous Process Decompression System (X STOP®) is not covered for Medicaid products.

Lymphedema–Pneumatic Compression Devices, Compression Garments, and Appliances: The following clarifying statement of coverage of segmented, calibrated gradient pneumatic compression device (HCPCS code E0652) was added to the policy: “The only time that a segmented, calibrated gradient pneumatic compression device (HCPCS code E0652) would be covered is when the individual has unique characteristics that prevent them from receiving satisfactory pneumatic compression treatment using a nonsegmented device in conjunction with a segmented appliance or a segmented compression device without manual control of pressure in each chamber.” A variation was added for MVP Medicaid Managed Care products. Only the following HCPCS codes are covered for Medicaid: E0650, E0655, E0660, E0665, and E0666.

Orthotic Devices (other than therapeutic diabetic footwear): There are no changes to the medical policy criteria.

Penile Implant for Erectile Dysfunction: There are no changes to the medical policy criteria.

Prosthetic Devices (External) Eye and Facial and Scleral Shells: There are no changes to the medical policy criteria.

Prostatic Urethral Lift (PUL) System UroLift® *NEW Policy*: Prostatic Urethral Lift (PUL) System UroLift® is a new policy effective December 1, 2017. The Urolift® System has not been established in peer review literature to improve health outcomes. It is, therefore, considered not medically

necessary for Medicare and Medicaid Products. There is a Medicare variation for prostatic urethral lift system (UroLift®). A prostatic urethral lift system is covered for Medicare members when the medical policy criteria is met.

Repetitive Transcranial Magnetic Stimulation (rTMS):

There are no changes to the medical policy criteria.

Sinus Surgery–Endoscopic: There are no changes to the medical policy criteria.

Medical Policies Approved Without Changes in October 2017

Audiologic Screening and Evoked Otoacoustic Emissions (OAE)

Canaloplasty and Viscocanalostomy

Cardiac Procedures

Ground Ambulance Services and Ambulette Services

Intraoperative Neurophysiologic Monitoring During Spinal Surgery

Guidelines for the Testing, Management, and Treatment of HIV/AIDS

As part of a continuing Quality Improvement Program, MVP has adopted the New York State Department of Health’s (NYSDOH) AIDS Institute’s recommendations for the prevention and management of HIV infection in adults, children, and adolescents, and the prevention of HIV transmission during the perinatal period.

The HIV/AIDS Guideline document contains an overview of testing, management, and treatment of HIV from different professional and regulatory organizations such as the NYSDOH and the American Congress of Obstetricians and Gynecologists (ACOG). There may be differences in recommendations regarding HIV testing among the organizations. Providers in New York State must follow the New York State requirements at a minimum.

The HIV/AIDS Guideline document lists several professional organization’s guidelines documents which include:

- NYSDOH’s AIDS Institute
- American Congress of Obstetricians and Gynecologists
- Primary Care Approach to the HIV-Infected Patient
- The NYSDOH HIV Testing During Pregnancy and Delivery Guideline
- The American Congress of Obstetricians and Gynecologists. Committee Opinion: Prenatal and

Perinatal Human Immunodeficiency Virus Testing:
Expanded Recommendations

- Centers for Disease Control MMWR Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings

The 2010 Amendment to the New York State HIV Testing Law Key Message

The 2010 Amendment to the New York State HIV Testing Law requires health care providers, including but not limited to physicians, physician assistants, nurse practitioners, and nurse midwives who are providing primary care services, to offer HIV testing to all persons ages 13–64 (or younger with risk factors). This must be done at least once and must be done more often if there is evidence of risk activity.

To access the guidelines, visit mvphealthcare.com and select *Providers*, then *Quality Programs*, then *Provider Quality Improvement Manual* and view the Infectious Disease section for Clinical Guidelines.

Pharmacy Updates

Policy Updates Effective January 1, 2018

Proton Pump Inhibitor Therapy: Omeprazole/Sodium Bicarbonate removed as prerequisite drug. Prescription history or chart notes must substantiate trial of preferred agents Crohn’s Disease and Ulcerative Colitis, Select Agents. Inflecta added to policy. Exclusion for more than one induction course added.

Irritable Bowel Syndrome *NEW Policy*: Prior authorization required for Xifaxan, Viberzi, and Lotronex. Viberzi moved to IBS policy.

Enteral Therapy New York: No changes.

Enteral Therapy Vermont: No changes.

Gaucher Disease Type 1: No changes.

Hereditary Angiodema: Ruconest dosing updated.

Chelating Agents: No changes.

Preventative Service-Medication: Added coverage of statins.

Spinraza *NEW Policy*

Topical Agents for Pruritus *NEW Policy*: Doxepin cream will require prior authorization.

Xifaxan: Criteria for IBS-D removed.

Formulary Updated for Commercial, Marketplace, and Medicaid

New drugs—recently FDA approved, prior authorization required, Tier 3, non-formulary for MVP Medicaid plans.

Drug Name	Indication
Haegarda	Hereditary Angioedema
Tremfya	Plaque Psoriasis
Nerlynx	Breast cancer
Vosevi	Hepatitis C
Idhifa	Leukemia
Mavyret	Hepatitis C
Besponsa	Leukemia
Mydayis	ADHD
Rituxan Hycela	Lymphoma/Leukemia
Benlysta	Lupus
Contempla	ADHD
Nityr	Hereditary tyrosinemia
Lynparza	Ovarian cancer
Armonair	Asthma
Vyxeos	Leukemia
Flolipid	Hyperlipidemia

Drugs Added to Formulary

Tier 1 for Commercial/Medicaid and Tier 2 for Marketplace

Melphalan
 Sevelamer tab
 Testosterone TD Solution
 Eletriptan
 Moxifloxacin-tier 1 marketplace
 Scopolamine Patch
 Mesalamine Dr
 Adaplene-Bebzoyl Peroxide
 Prasugrel

Drugs Removed from Prior Authorization

Rubraca
 Vemlidy
 Ocrevus